2025 - A year of Strategic Momentum

The 2025 Year: A Defining Moment for EFEVRE TECH

The year 2025 marked a defining moment for EFEVRE TECH—one focused not on promises but on execution. Across software, deep-tech hardware, EU-funded innovation, and strategic partnerships, this year validated our vision: to transform how advanced technology is designed, deployed, and trusted in real-world scientific and industrial environments.

From Concept to Completion: Software Platforms

In 2025, our two software platforms, VITALE and BioSkepsis AI, reached full maturity and successfully exited the testing phase.

VITALE: A Comprehensive Solution

VITALE was specifically engineered to address challenges in laboratory automation and data management. It offers an all-in-one solution that automates routine tasks, ensures proper sample handling, and provides real-time insights into ongoing experiments. VITALE empowers researchers to focus on what truly matters: groundbreaking discoveries. The platform underwent rigorous testing by early adopters in real-life scenarios and was successfully completed and submitted as an EU-funded project. It demonstrated its capacity to support advanced biomedical workflows, knowledge extraction, and decision support at scale.

BioSkepsis AI: Revolutionizing Research

BioSkepsis Artificial Intelligence derives its name from bio (biology) and skepsis (Greek for critical thinking). This advanced AI-driven research intelligence platform retrieves millions of new scientific articles from PubMed. It helps life-science researchers avoid spending countless hours sifting through abstracts, cross-referencing terms, and validating findings across multiple sources. BioSkepsis AI transforms how researchers, clinicians, and biotech innovators interact with biomedical knowledge.

In drug discovery, this platform helps identify molecular pathways connected to emerging therapies, enabling faster and more targeted development efforts. For disease research, it uncovers complex connections between genes, proteins, and disease biomarkers, providing scientists with a clearer understanding of disease mechanisms. In diagnostics development, BioSkepsis AI accelerates the validation of candidate markers by instantly summarizing literature evidence across thousands of publications. It also transforms the process of conducting literature reviews, providing structured, AI-assisted insights that save weeks of manual effort.

While this milestone closes an important chapter in 2025, it also sets the stage for what comes next in 2026 to introduce new releases that build on this foundation in unexpected and impactful ways.

Hardware Innovation Validated by the Market

A major highlight of the year was the commercial validation of our deep-tech hardware efforts. AMGEL4TT, our compact real-time laboratory device, achieved its first commercial sale to the Cancer Molecular Diagnostics Laboratory of the University of Cambridge.

The Technology Transfer device is a cutting-edge, modular laboratory automation workstation designed to revolutionize how novel molecular diagnostic applications transition from laboratory to market. Whether in academia, an R&D company, or a laboratory, AMGEL4TT streamlines the entire process, ensuring innovations do not remain confined to research. This milestone represents more than a sale transaction; it is independent confirmation that our engineering, design, and performance standards meet the expectations of one of the world’s leading research institutions.

Growing a Trusted Research Community

Our commitment to collaborative innovation continued through LIFESPIRIT, which reached its first 50 active member organizations in 2025. This growing network of laboratories, research centers, and industry stakeholders reflects a shared demand for interoperable, transparent, and AI-enabled research tools.

EU Projects, Pilots, and Partnerships

We marked the successful completion of the VITALE EU-funded project, alongside a year rich in:

• 1:1 live demonstration meetings and hands-on pilot testing

• Remote webinars, workshops, and training sessions

• Strategic collaborations with academic, industrial, and innovation partners

  
  

Closing 2025 and Looking Ahead

As we close 2025, EFEVRE TECH stands in a position of strength shaped by execution and validation. Our software platforms have decisively moved beyond development into tested, deployable solutions. Our hardware innovation has been proven in real research environments, and our growing community reflects a shared commitment to rigorous, technology-driven progress. Most importantly, the partnerships formed and strengthened throughout the year are grounded in trust, collaboration, and shared ambition.

The year ahead will build on this momentum with purpose. In 2026, our focus will turn to expansion, introducing new releases, deepening integrations across platforms, and scaling impact across industry and research ecosystems. Each step forward will continue to be guided by real-world needs, measurable outcomes, and a disciplined approach to innovation.

We extend our sincere appreciation to our clients, partners, investors, and collaborators for the confidence they placed in our work throughout this journey. 2025 was a year of delivery and proof. 2026 will be a year of acceleration and transforming validated foundations into lasting impact.

The Future of Life Science Research

As we look to the future, it is essential to recognize the role of technology in advancing life science research. The integration of AI and automation is not merely a trend; it is a necessity. These tools enhance our ability to conduct research efficiently and accurately. By adopting these innovations, we can address the reproducibility crisis in scientific research.

The phrase "AI-powered laboratory automation" encapsulates the future we envision. This future will empower researchers to achieve unprecedented levels of accuracy and efficiency. As we continue to innovate, we will remain committed to our mission of revolutionizing life-science research and diagnostics.

In conclusion, the journey we embarked on in 2025 is just the beginning. The advancements we have made in software and hardware are paving the way for a new era in life science research. We are excited about the possibilities that lie ahead and are dedicated to supporting our community in achieving their research goals. Together, we will shape the future of science.